<DOC>
	<DOCNO>NCT02624999</DOCNO>
	<brief_summary>Phase II , Randomized , Non-Inferiority Study Comparing Individualized Cancer Vaccine ( AlloVax™ ) Chemotherapy Subjects R/M SCCHN .</brief_summary>
	<brief_title>Study Comparing AlloVax™ Chemotherapy Recurrent/Metastatic Squamous Cell Carcinoma Head &amp; Neck</brief_title>
	<detailed_description>All accrue subject randomize 2:1 AlloVax™ ( CRCL + AlloStim™ ) immunotherapy vs. standard chemotherapy . AlloVax™ experimental individualize therapeutic vaccine show active study population . The standard chemotherapy arm ( Arm 1 ) receive six three-week cycle chemotherapy consist cisplatin day 0 3-week cycle dose 80-100 mg/m2 IV follow 1000 mg/m2 IV flurouracil ( 5FU ) day 1-4 cycle . The immunotherapy arm ( Arm 2 ) receive immunotherapy ( AlloVax™ ) twice week 4 week every 4 week additional 12 week . The study design powered determine AlloVax™ inferior active chemotherapy control .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Adult male female subject age 18 year old screen visit . Histopatholologically cytologically confirm diagnosis locoregionally recurrent unresectable previously untreated metastatic SCCHN . Tumor lesion safely accessible biopsy surgical excision result minimum 0.2 g tumor sample CRCL processing . Subjects must measurable disease accord revise RECIST v.1.1 guideline . Eastern Cooperative Oncology Group ( ECOG ) ≤1 . Subjects must screen negative Human Immunodeficiency Virus 1 ( HIV1 ) , HBsAg , Hepatitis C ( HCV ) Rapid Plasma Reagin ( RPR , syphilis ) . Subjects must adequate organ function include : ( WBC &gt; 3000/mm3 , Platelets &gt; 100,000/mm3 , Absolute neutrophil count ≥ 1,500/mm³ , Hemoglobin ≥ 10.0 g/dL ( transfusion allow ) ) , Hepatic ( Serum Total bilirubin &lt; 2 x ULN mg/dL , Alanine transaminase ( ALT ) ( SGPT ) / Aspartate aminotransferase ( AST ) ( SGOT ) ≤3 x upper limit normal ( ULN ) ) , Renal : Serum creatinine ( SCR ) &lt; 2.0 x ULN , , Creatinine clearance ( CCR ) &gt; 30 mL/min . Prestudy EKG without significant abnormality . Women childbearing potential must negative urine serum pregnancy test result within 72 hour prior start study drug administration . If child produce potential age , must agree use contraception avoidance pregnancy measure enrol study receive experimental product . Ability understand study , inherent risk , side effect potential benefit able give write informed consent participate . Clinical evidence radiological evidence brain metastasis . Treated another primary cancer within 2 year prior sign inform consent form . Any concomitant anticancer therapy . History severe hypersensitivity monoclonal antibody drug contraindication study drug . Concomitant active autoimmune disease ( e.g. , rheumatoid arthritis , multiple sclerosis , autoimmune thyroid disease , uveitis ) . Prior experimental therapy cancer vaccine treatment ( e.g. , dendritic cell therapy , heat shock vaccine ) . Clinical requirement systemic steroid immunosuppressive therapy , include : cyclosporine , antithymocyte globulin , tacrolimus within 1 month prior sign inform consent form . Uncontrolled intercurrent illness include , limited , ongoing active infection , require parenteral antibiotic , symptomatic congestive heart failure , severe myocardial insufficiency , cardiac arrhythmia . All infection must resolve subject must remain febrile seven day prior place study . History blood transfusion reaction . Psychiatric addictive disorder condition , opinion investigator , would preclude study participation . Female subject pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>SCCHN</keyword>
	<keyword>R/M SCCHN</keyword>
	<keyword>Carcinoma</keyword>
</DOC>